Onconetix (NASDAQ:ONCO – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($76.01) EPS for the quarter, topping analysts’ consensus estimates of ($45,050.00) by $44,973.99, FiscalAI reports. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.02 million. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%.
Onconetix Price Performance
NASDAQ:ONCO traded down $0.30 during trading hours on Monday, reaching $2.91. 62,174 shares of the stock were exchanged, compared to its average volume of 167,959. The stock has a market cap of $1.72 million, a PE ratio of 0.00 and a beta of 2.62. Onconetix has a twelve month low of $2.76 and a twelve month high of $1,610.00. The firm has a 50 day moving average of $6.24 and a 200 day moving average of $110.32.
Analyst Ratings Changes
A number of equities analysts have issued reports on ONCO shares. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. Wall Street Zen upgraded Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Onconetix currently has an average rating of “Sell”.
Check Out Our Latest Analysis on Onconetix
About Onconetix
Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.
Read More
- Five stocks we like better than Onconetix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
